Loading clinical trials...
Loading clinical trials...
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Conditions
Interventions
Induction Durvalumab
Chemotherapy
+2 more
Locations
5
United States
Rush University Medical Center
Chicago, Illinois, United States
Cancer Center of Kansas
Wichita, Kansas, United States
HealthPartners Institute
Minneapolis, Minnesota, United States
Summit Medical Group, P. A.
Berkeley Heights, New Jersey, United States
Providence Portland Medical Center
Portland, Oregon, United States
Start Date
June 18, 2020
Primary Completion Date
June 20, 2023
Completion Date
February 5, 2024
Last Updated
December 20, 2024
NCT06043817
NCT05671510
NCT07177937
NCT06426511
NCT06257264
NCT03563976
Lead Sponsor
Rachel Sanborn
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions